Cidara Therapeutics Announced Rezzayo (Rezafungin Acetate) Has Been Approved In The European Union For Invasive Candidiasis In Adults
Portfolio Pulse from Benzinga Newsdesk
Cidara Therapeutics announced that its drug Rezzayo (Rezafungin Acetate) has been approved by the European Union for the treatment of invasive candidiasis in adults. This marks the first new treatment option for this condition in over 15 years. Following the approval by the European Medicines Agency (EMA), Cidara is set to receive a milestone payment of approximately $11.14 million from Mundipharma.
December 22, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cidara Therapeutics' Rezzayo has been approved in the EU for invasive candidiasis, providing a new treatment option after 15 years. The company will receive a milestone payment of $11.14 million from Mundipharma.
The approval of Rezzayo in the EU is a significant regulatory milestone for Cidara Therapeutics, likely to be viewed positively by investors. The milestone payment of $11.14 million from Mundipharma is a substantial financial benefit and could provide a short-term boost to the company's stock price. The news is highly relevant and important due to the direct financial impact and the potential for increased market confidence in Cidara's product pipeline.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100